Provided by Tiger Trade Technology Pte. Ltd.

Biomarin Pharmaceutical

65.08
+0.35000.54%
Post-market: 65.280.2000+0.31%19:53 EDT
Volume:1.38M
Turnover:90.28M
Market Cap:12.58B
PE:171.72
High:66.21
Open:65.34
Low:64.97
Close:64.73
52wk High:70.98
52wk Low:49.26
Shares:193.27M
Float Shares:192.12M
Volume Ratio:0.75
T/O Rate:0.72%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3790
EPS(LYR):1.80
ROE:1.18%
ROA:3.26%
PB:1.99
PE(LYR):36.16

Loading ...

BioMarin Pharmaceutical Is Maintained at Neutral by HC Wainwright & Co.

Dow Jones
·
May 18

Analysts’ Opinions Are Mixed on These Healthcare Stocks: HealthStream (HSTM) and BioMarin Pharmaceutical (BMRN)

TIPRANKS
·
May 18

BUZZ-BioMarin falls after genetic disease therapy shows mixed results in study

Reuters
·
May 18

BioMarin price target lowered to $50 from $55 at H.C. Wainwright

TIPRANKS
·
May 18

Biomarin Pharmaceutical Inc. : H.c. Wainwright Cuts Target Price to $50 From $55

THOMSON REUTERS
·
May 18

BioMarin Pharmaceutical Reports No Functional Improvement in BMN 401 ENPP1 Deficiency Study

MT Newswires Live
·
May 18

Biomarin Pharmaceutical Shares Down 1% After Genetic Disease Therapy Shows Mixed Results in Late-Stage Study

THOMSON REUTERS
·
May 18

BioMarin’s BMN 401 meets 1 of 2 endpoints in Phase 3 ENPP1 trial

TIPRANKS
·
May 18

BioMarin's genetic disease therapy shows mixed results in late-stage study

Reuters
·
May 18

Biomarin Pharmaceutical Inc - Energy 3 Study Meets 1 of 2 Co-Primary Endpoints in Enpp1 Deficiency

THOMSON REUTERS
·
May 18

Biomarin Pharmaceutical Inc - Bmn 401 Generally Well-Tolerated With No New Safety Signals Reported

THOMSON REUTERS
·
May 18

Biomarin Pharmaceutical Inc - No Improvement in Radiagraphic Global Impression of Change Scores in Energy 3 Study

THOMSON REUTERS
·
May 18

Biomarin Provides Update on Phase 3 Trial for Bmn 401 in Children Aged 1-12 With Enpp1 Deficiency

THOMSON REUTERS
·
May 18

Biomarin Pharmaceutical Inc - Bmn 401 Shows Significant Increase in Plasma Inorganic Pyrophosphate in Energy 3 Study

THOMSON REUTERS
·
May 18

Biomarin Pharmaceutical Inc - Evaluating Data to Determine Next Steps for Bmn 401

THOMSON REUTERS
·
May 18

Biomarin Pharmaceutical Inc - No Positive Trends in Secondary Endpoints Including Rickets Severity Score and Growth Z-Score

THOMSON REUTERS
·
May 18

BioMarin Extends BMN 351 Duchenne Study, Keeping Long-Term Data in Focus for Investors

TIPRANKS
·
May 15

Zura Bio appoints Muzammil Mustufa chief business officer

Reuters
·
May 13

BioMarin EVP, Chief R&D Officer Gregory R. Friberg disposes 3,281 shares for $176,666.85

Reuters
·
May 12

BioMarin Pharmaceutical Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
May 08